Navigation Links
US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
Date:9/11/2008

New Indications and Products Offset Patent Expirations

SAN FRANCISCO, Sept. 11 /PRNewswire/ -- The U.S. market for drug treatment of major neuropathic pain (NP) conditions is currently valued at $2.6 billion, according to US Neuropathic Pain, a report released today by WWMR, Inc. Growth over the past four years has been driven largely by the successful launch of Lyrica (pregabalin) for diabetic neuropathic pain and post-herpetic neuralgia in December 2004 along with its 2007 approval for fibromyalgia, as well as the launch of Lilly's Cymbalta (duloxetine) for diabetic neuropathic pain in 2004. The additional June 2008 approval of Cymbalta for fibromyalgia will spur penetration of this prevalent condition.

Based on a decade of experience tracking and forecasting the NP Market, WWMR predicts healthy growth over the next 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit of an additional mechanism of action. Growth will slow between 2013 and 2018 as Lyrica and Cymbalta patents expire, and the fibromyalgia market penetration becomes saturated. Additional launch of novel compounds and new brands of existing drug classes will be required in order to sustain market growth.

The US neuropathic pain market consists of 4.7 million patients, and is expected to grow to more than 6.1 million patients, and be valued at $5.1 billion in 2018. With the addition of two key new indications to this report (Fibromyalgia and Neuropathic Cancer Pain) patient population estimates and projections as well as market value and projections, are available for a total of ten Neuropathic Pain Conditions (neuropathic back pain, fibromyalgia, diabetic neuropathy, neuropathic cancer pain, complex regional pain syndrome, HIV/AIDS neuropathy, post-herpetic neuralgia, phantom limb pain, spinal cord injury, and trigeminal neuralgia). Insights have also been added from WWMR's US Pain Clinic Monitor -- an audit of more than 100 pain clinics containing prescribing and condition details on more than 5000 patients -- many of whom have neuropathic pain.

Worldwide, approximately 76 agents are in active clinical trials for the treatment of neuropathic pain, and are reviewed in this report. Five new neuropathic pain treatments are currently registered or pre-registered with the FDA for NP marketing approval: lacosamide (Schwarz Pharma), milnacipran (Forest Laboratories/Cypress Bioscience), transdermal capsaicin (NeurogesX) and a dual cannabinoid receptor agonist (GW/Bayer), and fentanyl buccal (Cephalon). Eighteen drugs are in Phase III development in the US including two GABA receptor agonists pregabalin (Pfizer) and gabapentin GR (Depomed); a sodium channel antagonist mexiletine (Boehringer Ingelheim); three glutamate / NMDA antagonists ketamine intranasal (Javelin), a dextromethorphan/quinidine combination (Avanir), and NP-1 (EpiCept/Epitome); two serotonin/norepinephrine reuptake inhibitors desvenlafaxine (Wyeth), and paroxetine (GSK/Novo Nordisk); an alpha-2 adrenergic receptor antagonist/norepinehrine reuptake inhibitor reboxetine (Pfizer); an opioid receptor agonist/norepinephrine reuptake inhibitor tapentadol (Ortho-McNeil); a dopamine receptor agonist sodium oxybate (Jazz), and a neuromuscular blocking agent botulinum toxin A (Allergan). Early-phase products are also described in the full report.

ADDITIONAL SERVICES AND REPORTS BY WWMR, INC. INCLUDE:

-- US Pain Clinic Monitor (available now)

-- 2008 European Neuropathic Pain (coming soon)

-- 2008 Japanese Neuropathic Pain (coming soon)

WWMR, Inc. is a leader in Pain Reporting, and also designs and executes research which brings clarity, reveals innovative opportunities and provides deeper understanding across many therapy areas and all phases of drug development. This enables our clients to:
-- Demonstrate the commercial value of product/partnering opportunities

-- Optimize the revenue potential of their product portfolio

-- Identify and evaluate additional business opportunities

ABOUT WWMR, INC. (WORLDWIDE MARKETING RESEARCH):

A highly-regarded marketing research and strategic consulting firm with global capabilities. Since 1994, WWMR has provided thousands of insightful, proprietary studies to pharmaceutical, biotech, medical device, and diagnostics companies worldwide. Using primary and secondary research methodologies, WWMR provides insights on current and emerging markets using their expertise in product and technology assessments, forecast modeling, epidemiology projections, product launch monitoring (pre- and post-), primary marketing research and medical economic analyses.

For more information, contact:

Michelle Nordstrom

WWMR, Inc.

2929 Campus Drive

Suite 200

San Mateo, CA 94403

Phone: (888) 947-2339

(650) 513-0300

Fax: (650) 312-1570

Web: http://www.WWMR.com

Email: Michelle_Nordstrom@WWMR.com


'/>"/>
SOURCE WWMR, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
3. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
4. US Facet Fixation Market to Increase by Over 60% Annually Through 2012
5. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
6. Injectable CTM Manufacturing Market Report Now Available
7. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
8. SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Filter Markets - Discover the Growth Segments
10. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):